OXiGENE Promotes Senior Executive
WALTHAM, Mass., July 15, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, today announced the promotion of
John A. Kollins to the position of Chief Operating Officer.
Mr. Kollins, who most recently served as OXiGENE's Senior Vice-President and
Chief Business Officer, will continue to lead the company's business and
corporate development initiatives, and in addition will assume responsibility
for the company's operations.
"Since joining OXiGENE in March 2007, John has made numerous contributions to
the company, and has significantly advanced our corporate and business
development initiatives," commented Richard Chin, M.D., OXiGENE's President and
CEO. "I am very pleased to congratulate John on his promotion, and am confident
in his ability to contribute further to OXiGENE in his new role."
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing VDAs that selectively disrupt abnormal blood vessels associated with
solid tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property and therapeutic development expertise to
bring life-extending and -enhancing medicines to patients.
The OXiGENE, Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=4969
CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
415-315-9413
medwards@oxigene.com
OXiGENE Promotes Senior Executive
| Source: Oxigene, Inc.